sirtex major positive news today Sirtex Medical SRX got more...

sirtex major positive news today Sirtex Medical SRX got more major positive news today that will lead to more usage of Sirtex as Billion dollars Genentech drug Avastin got expanded indications in being used with 5 FU and/or Irinotecan both of which are currently used with Sirtex Sir Spheres and which will dramatically lead to increased usage of Sir Spheres with Avastin also as Sir Spheres are already approved and the trial results for all of these have been very positive. The Genentech exposure with using Sir Spheres and Avastin will dramatically upgrade sales for Sir Spheres and Sirtex also as this Avastin is also a multibillion dollars product and is now being used synergistically with Sir Spheres for metastatic colorectal cancer to the liver. It now looks rather apparent the major licensind deal will be with Genentech and probably likely as the ultimate acquirer of Sirtex. As others realize this outcome I may be forced to buy on the ask now before the news catches on. here are the links



Avastin Gets Extended Approval

By Althea Chang
TheStreet.com Staff Reporter
6/21/2006 2:40 PM EDT
Click here for more stories by Althea Chang




Genentech's (DNA:NYSE - commentary - research - Cramer's Take) cancer drug Avastin has been approved by U.S. regulators to help treat cases of colorectal cancer that have spread to other parts of the body and that haven't responded to prior medications.

The approval by the Food and Drug Administration was based on a study of 829 patients with advanced or metastatic colorectal cancer. The patients had received treatment with a type of chemotherapy regimen called 5-FU plus the drug irinotecan as an initial therapy, in some cases in addition to surgery.

Patients who received Avastin plus chemo saw a 25% reduction in the risk of death, which is equivalent to a 33% improvement in overall survival, compared with who received chemotherapy alone, the company said late Tuesday. Colorectal cancer is the second-leading cause of cancer death in the U.S.

"Avastin used in combination with chemotherapy has become an important component of care for patients with metastatic colorectal cancer," said Dr. Hal Barron, Genentech's chief medical officer, who adds that the "new indication offers CRC patients who have received a previous treatment regimen a new option to help fight their disease."

The median survival time for those who received Avastin was 13 months, compared with 10.8 months for patients getting only chemo. Among cancer therapies, extending a life for two months is considered significant. Since the figure is a median, some patients see little or no benefit to therapies with Avastin, while others see significant gains.

Genentech's shares were up 89 cents, or 1.2%, to $77.79.

Genentech is also studying the drug's effectiveness in a number of phase III trials for kidney, breast, pancreatic, nonsmall-cell lung, prostate and ovarian cancers. Phase III is the stage of trials conducted immediately before a drug is submitted to the FDA for marketing approval.

Go to NEXT PAGE Yahoo! My Yahoo! Mail Make Yahoo! your home page
Sign In
New User?Sign Up
Finance Home - Help



HomeInvestingNews & CommentaryRetirement & PlanningBanking & CreditLoansTaxesSpecial EditionsColumnistsPersonal FinanceInvesting IdeasMarketsCompany FinancesProvidersGet QuotesSymbol LookupFinance Search



Press Release Source: Genentech, Inc.


FDA Approves Avastin(R) in Combination With Chemotherapy for Second-Line Metastatic Colorectal Cancer Patients
Tuesday June 20, 7:32 pm ET


SOUTH SAN FRANCISCO, Calif., June 20 /PRNewswire-FirstCall/ -- Genentech, Inc. (NYSE: DNA - News) announced today that the U.S. Food and Drug Administration (FDA) approved Avastin® (bevacizumab) in combination with intravenous 5-fluorouracil (5-FU)-based chemotherapy for second-line metastatic colorectal cancer. Avastin is also approved as a first-line treatment of metastatic colorectal cancer (CRC) in combination with intravenous 5-FU-based chemotherapy.
ADVERTISEMENT


"Avastin is the only biologic therapy with a demonstrated survival benefit in colorectal cancer, and this new indication offers CRC patients who have received a previous treatment regimen a new option to help fight their disease," said Hal Barron, M.D., senior vice president, Development and chief medical officer at Genentech. "Avastin used in combination with chemotherapy has become an important component of care for patients with metastatic colorectal cancer. We continue to study Avastin in both the adjuvant and metastatic settings, and Phase III trials in kidney, breast, pancreatic, non-small cell lung, prostate and ovarian cancers are ongoing in the hope that we may be able to help patients with other cancers as well."

The approval is based on results of a randomized, controlled, multicenter Phase III trial (E3200) of 829 patients with advanced or metastatic CRC who had received previous treatment with irinotecan and 5-FU as initial therapy for metastatic disease or as adjuvent therapy. The study showed that patients who received Avastin plus the 5-FU-based chemotherapy regimen known as FOLFOX4 (oxaliplatin/5-FU/leucovorin) had a 25 percent reduction in the risk of death (based on a hazard ratio of 0.75), the primary endpoint, which is equivalent to a 33 percent improvement in overall survival, compared to patients who received FOLFOX4 alone. Median survival for patients receiving Avastin plus FOLFOX4 was 13.0 months, compared to 10.8 months for those receiving FOLFOX4 alone.

"Colorectal cancer is the second leading cause of cancer death in the United States, so we are encouraged by new treatments and options that are leading to increased survival for patients," said Amy E. Kelly, Co-founder and Executive Director of the Colon Cancer Alliance. "We believe Avastin is an important advance that offers hope for prolonging survival for patients, including those who have already been through first-line treatment."

In the E3200 study, the most common Grade 3-5 (non-hematologic) and Grade 4/5 (hematologic) adverse events which occurred at a higher incidence (>/= 2 percent) in the Avastin plus FOLFOX4 arm, compared to the FOLFOX4 alone arm, were: diarrhea, nausea, vomiting, dehydration, ileus, sensory neuropathy, other neurologic events, fatigue, abdominal pain, headache, hypertension and hemorrhage.

The trial was sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, and conducted by a network of researchers led by the Eastern Cooperative Oncology Group (ECOG). Genentech provided Avastin for the trial under the Cooperative Research and Development Agreement (CRADA) with the NCI for the clinical development of Avastin, as well as financial support for data management.

About Avastin

Avastin is a therapeutic antibody designed to inhibit Vascular Endothelial Growth Factor (VEGF), a protein that plays an important role in tumor angiogenesis and maintenance of existing tumor vessels. By inhibiting VEGF, Avastin is designed to interfere with the blood supply to a tumor, a process that is thought to be critical to a tumor's growth and metastasis. For full prescribing information and boxed warnings on Avastin and information about angiogenesis, visit http://www.gene.com. For more information on Avastin, visit http://www.avastin.com.

Avastin, in combination with intravenous 5-FU-based chemotherapy, is indicated for first- or second-line treatment of patients with metastatic carcinoma of the colon or rectum. The FDA first approved Avastin on February 26, 2004 as a first-line treatment for metastatic colorectal cancer in combination with intravenous 5-FU-based chemotherapy. Approval was based on data from two trials. The pivotal trial was a large, placebo-controlled, randomized study that demonstrated a prolongation in the median survival of patients treated with Avastin plus the IFL (5-FU/leucovorin/CPT-11) chemotherapy regimen by approximately five months, compared to patients treated with the IFL chemotherapy regimen alone (20.3 months versus 15.6 months). The addition of Avastin to IFL improved overall survival by 52 percent (based on a hazard ratio of 0.66). In addition, this study demonstrated an improvement in progression-free survival of more than four months (10.6 months in the Avastin/IFL arm compared to 6.2 months in the IFL-alone arm).

Avastin Safety

Avastin has a well-established safety profile. In Genentech-sponsored studies, the most serious adverse events associated with Avastin were gastrointestinal perforation, wound healing complications, hemorrhage, arterial thromboembolic events, hypertensive crisis, nephrotic syndrome and congestive heart failure. The most common adverse events in patients receiving Avastin were asthenia, pain, abdominal pain, headache, hypertension, diarrhea, nausea, vomiting, anorexia, stomatitis, constipation, upper respiratory infection, epistaxis, dyspnea, exfoliative dermatitis, and proteinuria.

About the Avastin Development Program

Based on data showing that VEGF may play a broad role in a range of cancers, Genentech is pursuing a broad development program for Avastin that currently includes 130 clinical trials across 25 different types of cancer. Avastin is being evaluated in Phase III clinical trials for its potential use in adjuvant and metastatic colorectal, renal cell (kidney), breast, pancreatic, non-small cell lung, prostate and ovarian cancers. Avastin is also being evaluated in earlier stage trials as a potential therapy in a variety of solid tumor cancers and hematologic malignancies. In April 2006, Genentech submitted an sBLA for Avastin plus platinum-based chemotherapy for first-line treatment of advanced non-small cell lung cancer other than predominant squamous histology. In May 2006, Genentech submitted an sBLA for Avastin in combination with taxane chemotherapy for patients who have not previously received chemotherapy for their locally recurrent or metastatic breast cancer. For further information about Avastin clinical trials, please call 888-662-6728.

About VEGF and Tumor Angiogenesis

Genentech is a leader in research and product development in the area of angiogenesis, the process by which new blood vessels are formed. The link between angiogenesis and cancer growth has been discussed by many researchers for decades. It wasn't until 1989 that a key growth factor influencing the process, VEGF, was discovered by Napoleone Ferrara, M.D., a staff scientist at Genentech. Dr. Ferrara and his team at Genentech cloned VEGF, providing some of the first evidence that a specific angiogenic growth factor existed. This research was published in the journal Science in 1989. Dr. Ferrara then created a mouse antibody to this protein.

In 1993, in a study published in Nature, Dr. Ferrara and his team demonstrated that the antibody directed against VEGF could suppress angiogenesis and tumor growth in preclinical models, providing compelling evidence that VEGF can play a critical role in tumor growth. Clinical studies with a humanized version of the antibody, Avastin, began in 1997.

About Colorectal Cancer

According to the American Cancer Society (ACS), more than 150 patients die every day from colorectal cancer in the United States. Colorectal cancer is the second leading cause of cancer death in the United States and the third most frequently diagnosed cancer. The ACS estimates there will be 148,610 new cases of colorectal cancer diagnosed and 55,170 colorectal cancer deaths in 2006.

Genentech's Commitment to Patient Access

Genentech is committed to assisting eligible patients in accessing our therapies for approved indications, regardless of their ability to pay. Although Genentech's products are covered by most government and private insurance, Genentech established the Genentech® Access to Care Foundation (GATCF) in 1990 for its marketed products, and donates free product to eligible uninsured patients in the United States, except for Pulmozyme® (dornase alfa, recombinant), which is covered by the Genentech Endowment for Cystic Fibrosis. Genentech has provided more than $700 million in free drug to patients since 1990. In 2005 alone, GATCF supported over 18,000 patients by providing approximately $200 million of free product. Genentech recently donated more than $21 million to several independent public charities that provide financial assistance to eligible patients who cannot access needed medical treatment due to co-pay costs. To learn more about these independent, public charities and potential financial assistance options, patients can speak with an Alternative Funding Specialist from Genentech's Single Point of Contact (SPOC) group by calling 888-249-4918 or visiting http://www.SPOConline.com.

About Genentech BioOncology

Genentech is committed to changing the way cancer is treated by establishing a broad oncology portfolio of innovative, targeted therapies with the goal of improving patients' lives. The company is the leading provider of anti-tumor therapeutics in the United States. Genentech is conducting clinical development programs for Rituxan® (Rituximab), Herceptin® (Trastuzumab), Avastin® (bevacizumab), and Tarceva® (erlotinib), and markets all four products in the United States, either alone (Avastin and Herceptin) or with Biogen Idec Inc. (Rituxan) or OSI Pharmaceuticals, Inc. (Tarceva).

The company has a robust pipeline of potential oncology therapies with a focus on four key areas: angiogenesis, apoptosis (i.e., programmed cell death), the HER pathway, and B-cell biology. An investigational antibody directed at the HER pathway is currently in Phase II trials. In early development, are a small molecule directed at the hedgehog pathway and an investigational agent targeting apoptosis.

Founded 30 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics for significant unmet medical needs. A considerable number of the currently approved biotechnology products originated from or are based on Genentech science. Genentech manufactures and commercializes multiple biotechnology products and licenses several additional products to other companies. The company has headquarters in South San Francisco, Calif., and is listed on the New York Stock Exchange under the symbol DNA. For additional information about the company, please visit http://www.gene.com.

For the full prescribing information for Tarceva and the full prescribing information and Boxed Warnings for Rituxan, Herceptin, and Avastin, please visit http://www.gene.com.

This press release contains forward-looking statements regarding Avastin as a potential treatment for cancer. Such statements are predictions and involve risks and uncertainties such that actual results may differ materially. Among other things, Avastin's potential as a cancer treatment could be affected by unexpected safety, efficacy or manufacturing issues, additional time requirements for data analysis, BLA preparation and decision- making, discussions with the FDA or FDA actions, failure to receive FDA approval, competition, reimbursement, pricing, the ability to supply product, or product withdrawal. Please also refer to Genentech's periodic reports filed with the Securities and Exchange Commission. Genentech disclaims, and does not undertake, any obligation to update or revise the forward-looking statements in this press release.

Media Contact: Krysta Pellegrino 650-225-8226

Investor Contact: Sue Morris 650-225-6523

Advocacy Contact: Kristin Reed 650-467-9831




--------------------------------------------------------------------------------
Source: Genentech, Inc.


Email Story
Set News Alert
Print Story






Sponsor Results
Schedule D and Capital Gains Made Easy
Schedule D, corporate actions and wash sales are automated in Gainskeeper's unique portfolio tracking service. Gainskeeper increases investment returns by reducing tax liability.
www.gainskeeper.com
Get Tax Return Help
Find the right financial advisor for your financial goals in your area with AdvisorNow.com: Free matching service.
www.advisornow.com
TurboTax: Tax Return
Easy online tax return preparation from the tax software rated #1 by PC Magazine. Includes step-by-step guidance and double-checks your return for errors, start now.
www.turbotax.com

(What's This?)



Related Quote
DNA 77.63 +0.70 News
View Detailed Quote
Delayed 20 mins
Providers - Disclaimer


Related News Stories
· Genentech's Avastin gets label expansion from FDA - at MarketWatch (Wed Jun 21)
· Genentech Up on FDA Approval - AP (Wed Jun 21)
· Avastin Gets Extended Approval - at TheStreet.com (Wed Jun 21)
· Ahead of the Bell: Genentech - AP (Wed Jun 21)
More...

--------------------------------------------------------------------------------

· By industry: Biotechnology






Top Stories
· Group Said to Offer $10.7B for Univision - AP (Wed Jun 21)
· Morgan Stanley Profit More Than Doubles - AP (Wed Jun 21)
· FedEx, Morgan Stanley Help Dow Gain 100 - AP (Wed Jun 21)
· Ford Unveils 2007 Automobile Lineup - AP (Wed Jun 21)
More...

--------------------------------------------------------------------------------

· Most-emailed articles
· Most-viewed articles




RSS Feeds
Add headlines to your
personalized My Yahoo! Page
( About My Yahoo! and RSS )

DNA Headlines
My Yahoo RSS Biotechnology Headlines
My Yahoo RSS More Finance RSS Feeds




--------------------------------------------------------------------------------

Copyright © 2006 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Ad Feedback
Copyright © 2006 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.